Role of gastrin-peptides in Barrett's and colorectal carcinogenesis

World Journal of Gastroenterology

Volumn 18, Issue 45, 2012, Pages 6560-6570

  Chueca, Eduardo ^a   Lanas, Angel ^a,b,c,d   Piazuelo, Elena ^a,b,c  

^a INSTITUTO DE INVESTIGACIÓN SANITARIA ARAGÓN IIS ARAGÓN   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSITY OF ZARAGOZA   (Spain)

^d HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

Author keywords

Barrett's esophagus; C terminal flanking peptide; Colorectal cancer; Esophageal adenocarcinoma; Gastrin; Glycine extended gastrins; Hypergastrinemia; Progastrin; Proton pump inhibitors

Indexed keywords

ANTACID AGENT; AZOXYMETHANE; CARBOXYPEPTIDASE H; CHOLECYSTOKININ A RECEPTOR; CHOLECYSTOKININ B RECEPTOR; CHOLECYSTOKININ RECEPTOR; CYCLOOXYGENASE 2; FURIN; GASTRIN; GASTRIN 17; GASTRIN 34; GASTRIN RELEASING PEPTIDE; HISTAMINE H2 RECEPTOR ANTAGONIST; LIPOCORTIN 2; MITOGEN ACTIVATED PROTEIN KINASE; OMEPRAZOLE; PHOSPHATIDYLINOSITOL 3 KINASE; PROGASTRIN; PROTON PUMP INHIBITOR; UNCLASSIFIED DRUG;

APOPTOSIS; AUTOCRINE EFFECT; BARRETT ESOPHAGUS; CANCER RISK; CARCINOGENESIS; CELL PROLIFERATION; COLORECTAL CANCER; COLORECTAL CARCINOMA; ESOPHAGEAL ADENOCARCINOMA; GASTRIN CELL; GASTROESOPHAGEAL REFLUX; HUMAN; HYPERGASTRINEMIA; HYPERPLASIA; NONHUMAN; PEPTIDE SYNTHESIS; REVIEW; STOMACH ACID SECRETION; TUMOR GROWTH;

EID: 84873899553     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v18.i45.6560     Document Type: Review

References (98)

1. Beales IL, Ogunwobi OO. Glycine-extended gastrin inhibits apoptosis in Barrett's oesophageal and oesophageal adenocarcinoma cells through JAK2/STAT3 activation. J Mol Endocrinol 2009; 42: 305-318
2. Cobb S, Wood T, Ceci J, Varro A, Velasco M, Singh P. Intestinal expression of mutant and wild-type progastrin significantly increases colon carcinogenesis in response to azoxymethane in transgenic mice. Cancer 2004; 100: 1311-1323
3. Colucci R, Blandizzi C, Tanini M, Vassalle C, Breschi MC, Del Tacca M. Gastrin promotes human colon cancer cell growth via CCK-2 receptor-mediated cyclooxygenase-2 induction and prostaglandin E2 production. Br J Pharmacol 2005; 144: 338-348
4. Haigh CR, Attwood SE, Thompson DG, Jankowski JA, Kirton CM, Pritchard DM, Varro A, Dimaline R. Gastrin induces proliferation in Barrett's metaplasia through activation of the CCK2 receptor. Gastroenterology 2003; 124: 615-625
5. Wang TC, Koh TJ, Varro A, Cahill RJ, Dangler CA, Fox JG, Dockray GJ. Processing and proliferative effects of human progastrin in transgenic mice. J Clin Invest 1996; 98: 1918-1929
6. Merchant JL, Demediuk B, Brand SJ. A GC-rich element confers epidermal growth factor responsiveness to transcription from the gastrin promoter. Mol Cell Biol 1991; 11: 2686-2696
7. Brand SJ, Stone D. Reciprocal regulation of antral gastrin and somatostatin gene expression by omeprazole-induced achlorhydria. J Clin Invest 1988; 82: 1059-1066
8. McColl KE, Fullarton GM, Chittajalu R, el Nujumi AM, MacDonald AM, Dahill SW, Hilditch TE. Plasma gastrin, daytime intragastric pH, and nocturnal acid output before and at 1 and 7 months after eradication of Helicobacter pylori in duodenal ulcer subjects. Scand J Gastroenterol 1991; 26: 339-346
9. Mulholland G, Ardill JE, Fillmore D, Chittajallu RS, Fullarton GM, McColl KE. Helicobacter pylori related hypergastrinaemia is the result of a selective increase in gastrin 17. Gut 1993; 34: 757-761
10. Smith JT, Pounder RE, Nwokolo CU, Lanzon-Miller S, Evans DG, Graham DY, Evans DJ. Inappropriate hypergastrinaemia in asymptomatic healthy subjects infected with Helicobacter pylori. Gut 1990; 31: 522-525
11. Bloom SR, Mortimer CH, Thorner MO, Besser GM, Hall R, Gomez-Pan A, Roy VM, Russell RC, Coy DH, Kastin AJ, Schally AV. Inhibition of gastrin and gastric-acid secretion by growth-hormone release-inhibiting hormone. Lancet 1974; 2: 1106-1109
12. Wiborg O, Berglund L, Boel E, Norris F, Norris K, Rehfeld JF, Marcker KA, Vuust J. Structure of a human gastrin gene. Proc Natl Acad Sci USA 1984; 81: 1067-1069
13. Rehfeld JF, Zhu X, Norrbom C, Bundgaard JR, Johnsen AH, Nielsen JE, Vikesaa J, Stein J, Dey A, Steiner DF, Friis-Hansen L. Prohormone convertases 1/3 and 2 together orchestrate the site-specific cleavages of progastrin to release gastrin-34 and gastrin-17. Biochem J 2008; 415: 35-43
14. Varro A, Voronina S, Dockray GJ. Pathways of processing of the gastrin precursor in rat antral mucosa. J Clin Invest 1995; 95: 1642-1649
15. Brand SJ, Klarlund J, Schwartz TW, Rehfeld JF. Biosynthesis of tyrosine O-sulfated gastrins in rat antral mucosa. J Biol Chem 1984; 259: 13246-13252
16. Rehfeld JF. The art of measuring gastrin in plasma: a dwindling diagnostic discipline? Scand J Clin Lab Invest 2008; 68: 353-361
17. Rehfeld JF, Friis-Hansen L, Goetze JP, Hansen TV. The biology of cholecystokinin and gastrin peptides. Curr Top Med Chem 2007; 7: 1154-1165
18. Walsh JH, Isenberg JI, Ansfield J, Maxwell V. Clearance and acid-stimulating action of human big and little gastrins in duodenal ulcer subjects. J Clin Invest 1976; 57: 1125-1131
19. Goetze JP, Nielsen FC, Burcharth F, Rehfeld JF. Closing the gastrin loop in pancreatic carcinoma: coexpression of gastrin and its receptor in solid human pancreatic adenocarcinoma. Cancer 2000; 88: 2487-2494
20. Nemeth J, Taylor B, Pauwels S, Varro A, Dockray GJ. Identification of progastrin derived peptides in colorectal carcinoma extracts. Gut 1993; 34: 90-95
21. Rehfeld JF, Bardram L, Hilsted L. Gastrin in human bronchogenic carcinomas: constant expression but variable processing of progastrin. Cancer Res 1989; 49: 2840-2843
22. Siddheshwar RK, Gray JC, Kelly SB. Plasma levels of progastrin but not amidated gastrin or glycine extended gastrin are elevated in patients with colorectal carcinoma. Gut 2001; 48: 47-52
23. Reubi JC, Schaer JC, Waser B. Cholecystokinin(CCK)-A and CCK-B/gastrin receptors in human tumors. Cancer Res 1997; 57: 1377-1386
24. Singh P, Owlia A, Espeijo R, Dai B. Novel gastrin receptors mediate mitogenic effects of gastrin and processing intermediates of gastrin on Swiss 3T3 fibroblasts. Absence of detectable cholecystokinin (CCK)-A and CCK-B receptors. J Biol Chem 1995; 270: 8429-8438
25. Walsh JH. Physiology and pathophysiology of gastrin. Mt Sinai J Med 1992; 59: 117-124
26. Moore TC, Jepeal LI, Boylan MO, Singh SK, Boyd N, Beer DG, Chang AJ, Wolfe MM. Gastrin stimulates receptor-mediated proliferation of human esophageal adenocarcinoma cells. Regul Pept 2004; 120: 195-203
27. Rengifo-Cam W, Singh P. Role of progastrins and gastrins and their receptors in GI and pancreatic cancers: targets for treatment. Curr Pharm Des 2004; 10: 2345-2358
28. Singh P, Lu X, Cobb S, Miller BT, Tarasova N, Varro A, Owlia A. Progastrin1-80 stimulates growth of intestinal epithelial cells in vitro via high-affinity binding sites. Am J Physiol Gastrointest Liver Physiol 2003; 284: G328-G339
29. Singh P, Wu H, Clark C, Owlia A. Annexin II binds progastrin and gastrin-like peptides, and mediates growth factor effects of autocrine and exogenous gastrins on colon cancer and intestinal epithelial cells. Oncogene 2007; 26: 425-440
30. Singh P. Role of Annexin-II in GI cancers: interaction with gastrins/progastrins. Cancer Lett 2007; 252: 19-35
31. Todisco A, Takeuchi Y, Urumov A, Yamada J, Stepan VM, Yamada T. Molecular mechanisms for the growth factor action of gastrin. Am J Physiol 1997; 273: G891-G898
32. Smith KA, Patel O, Lachal S, Jennings I, Kemp B, Burgess J, Baldwin GS, Shulkes A. Production, secretion, and biological activity of the C-terminal flanking peptide of human progastrin. Gastroenterology 2006; 131: 1463-1474
33. Stepan VM, Sawada M, Todisco A, Dickinson CJ. Glycineextended gastrin exerts growth-promoting effects on human colon cancer cells. Mol Med 1999; 5: 147-159
34. Havu N, Mattsson H, Ekman L, Carlsson E. Enterochromaffin-like cell carcinoids in the rat gastric mucosa following long-term administration of ranitidine. Digestion 1990; 45: 189-195
35. Brunner GH, Lamberts R, Creutzfeldt W. Efficacy and safety of omeprazole in the long-term treatment of peptic ulcer and reflux oesophagitis resistant to ranitidine. Digestion 1990; 47 Suppl 1: 64-68; discussion 76
36. Obszynska JA, Atherfold PA, Nanji M, Glancy D, Santander S, Graham TA, Otto WR, West K, Harrison RF, Jankowski JA. Long-term proton pump induced hypergastrinaemia does induce lineage-specific restitution but not clonal expansion in benign Barrett's oesophagus in vivo. Gut 2010; 59: 156-163
37. Klinkenberg-Knol EC, Festen HP, Jansen JB, Lamers CB, Nelis F, Snel P, Lückers A, Dekkers CP, Havu N, Meuwissen SG. Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med 1994; 121: 161-167
38. Koop H, Klein M, Arnold R. Serum gastrin levels during long-term omeprazole treatment. Aliment Pharmacol Ther 1990; 4: 131-138
39. Nemeth J, Varro A, Bridson J, Walker R, Dockray GJ. Increased tissue concentrations of the gastrin precursor in patients treated with omeprazole. Eur J Clin Invest 1992; 22: 638-644
40. Kermorgant S, Lehy T. Glycine-extended gastrin promotes the invasiveness of human colon cancer cells. Biochem Biophys Res Commun 2001; 285: 136-141
41. Mattsson H, Havu N, Bräutigam J, Carlsson K, Lundell L, Carlsson E. Partial gastric corpectomy results in hypergastrinemia and development of gastric enterochromaffinlikecell carcinoids in the rat. Gastroenterology 1991; 100: 311-319
42. Wang JS, Varro A, Lightdale CJ, Lertkowit N, Slack KN, Fingerhood ML, Tsai WY, Wang TC, Abrams JA. Elevated serum gastrin is associated with a history of advanced neoplasia in Barrett's esophagus. Am J Gastroenterol 2010; 105: 1039-1045
43. Watson SA, Smith AM. Hypergastrinemia promotes adenoma progression in the APC(Min-/+) mouse model of familial adenomatous polyposis. Cancer Res 2001; 61: 625-631
44. Abdalla SI, Lao-Sirieix P, Novelli MR, Lovat LB, Sanderson IR, Fitzgerald RC. Gastrin-induced cyclooxygenase-2 expression in Barrett's carcinogenesis. Clin Cancer Res 2004; 10: 4784-4792
45. Koh TJ, Field JK, Varro A, Liloglou T, Fielding P, Cui G, Houghton J, Dockray GJ, Wang TC. Glycine-extended gastrin promotes the growth of lung cancer. Cancer Res 2004; 64: 196-201
46. Konturek PC, Rembiasz K, Burnat G, Konturek SJ, Tusinela M, Bielanski W, Rehfeld J, Karcz D, Hahn E. Effects of cyclooxygenase-2 inhibition on serum and tumor gastrins and expression of apoptosis-related proteins in colorectal cancer. Dig Dis Sci 2006; 51: 779-787
47. Caplin M, Savage K, Khan K, Brett B, Rode J, Varro A, Dhillon A. Expression and processing of gastrin in pancreatic adenocarcinoma. Br J Surg 2000; 87: 1035-1040
48. van Solinge WW, Odum L, Rehfeld JF. Ovarian cancers express and process progastrin. Cancer Res 1993; 53: 1823-1828
49. Smith AM, Watson SA. Gastrin and gastrin receptor activation: an early event in the adenoma-carcinoma sequence. Gut 2000; 47: 820-824
50. Konturek PC, Nikiforuk A, Kania J, Raithel M, Hahn EG, Mühldorfer S. Activation of NFkappaB represents the central event in the neoplastic progression associated with Barrett' s esophagus: a possible link to the inflammation and overexpression of COX-2, PPARgamma and growth factors. Dig Dis Sci 2004; 49: 1075-1083
51. Ryberg B, Bishop AE, Bloom SR, Carlsson E, Håkanson R, Larsson H, Mattsson H, Polak JM, Sundler F. Omeprazole and ranitidine, antisecretagogues with different modes of action, are equally effective in causing hyperplasia of enterochromaffin-like cells in rat stomach. Regul Pept 1989; 25: 235-246
52. Ogunwobi OO, Beales IL. Glycine-extended gastrin stimu-lates proliferation via JAK2-and Akt-dependent NF-kappaB activation in Barrett's oesophageal adenocarcinoma cells. Mol Cell Endocrinol 2008; 296: 94-102
53. Creutzfeldt W, Lamberts R. Inter-relationship between serum gastrin levels, gastric mucosal histology and gastric endocrine cell growth. Digestion 1992; 51 Suppl 1: 76-81
54. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, Havu N, Festen HP, Liedman B, Lamers CB, Jansen JB, Dalenback J, Snel P, Nelis GF, Meuwissen SG. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996; 334: 1018-1022
55. Lamberts R, Creutzfeldt W, Strüber HG, Brunner G, Solcia E. Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis. Gastroenterology 1993; 104: 1356-1370
56. Hsing AW, Hansson LE, McLaughlin JK, Nyren O, Blot WJ, Ekbom A, Fraumeni JF. Pernicious anemia and subsequent cancer. A population-based cohort study. Cancer 1993; 71: 745-750
57. Harvey RF, Bradshaw MJ, Davidson CM, Wilkinson SP, Davies PS. Multifocal gastric carcinoid tumours, achlorhydria, and hypergastrinaemia. Lancet 1985; 1: 951-954
58. Sobhani I, Lehy T, Laurent-Puig P, Cadiot G, Ruszniewski P, Mignon M. Chronic endogenous hypergastrinemia in humans: evidence for a mitogenic effect on the colonic mucosa. Gastroenterology 1993; 105: 22-30
59. Orbuch M, Venzon DJ, Lubensky IA, Weber HC, Gibril F, Jensen RT. Prolonged hypergastrinemia does not increase the frequency of colonic neoplasia in patients with Zollinger-Ellison syndrome. Dig Dis Sci 1996; 41: 604-613
60. Thorburn CM, Friedman GD, Dickinson CJ, Vogelman JH, Orentreich N, Parsonnet J. Gastrin and colorectal cancer: a prospective study. Gastroenterology 1998; 115: 275-280
61. van Soest EM, van Rossum LG, Dieleman JP, van Oijen MG, Siersema PD, Sturkenboom MC, Kuipers EJ. Proton pump inhibitors and the risk of colorectal cancer. Am J Gastroenterol 2008; 103: 966-973
62. Dickinson CJ. Relationship of gastrin processing to colon cancer. Gastroenterology 1995; 109: 1384-1388
63. Tytgat GN. Does endoscopic surveillance in esophageal columnar metaplasia (Barrett's esophagus) have any real value? Endoscopy 1995; 27: 19-26
64. Jankowski JA, Harrison RF, Perry I, Balkwill F, Tselepis C. Barrett's metaplasia. Lancet 2000; 356: 2079-2085
65. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991; 265: 1287-1289
66. El-Serag HB, Aguirre TV, Davis S, Kuebeler M, Bhattacharyya A, Sampliner RE. Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus. Am J Gastroenterol 2004; 99: 1877-1883
67. Lagergren J, Bergström R, Lindgren A, Nyrén O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 340: 825-831
68. Ouatu-Lascar R, Fitzgerald RC, Triadafilopoulos G. Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression. Gastroenterology 1999; 117: 327-335
69. Souza RF, Krishnan K, Spechler SJ. Acid, bile, and CDX: the ABCs of making Barrett's metaplasia. Am J Physiol Gastrointest Liver Physiol 2008; 295: G211-G218
70. Harris JC, Clarke PA, Awan A, Jankowski J, Watson SA. An antiapoptotic role for gastrin and the gastrin/CCK-2 receptor in Barrett's esophagus. Cancer Res 2004; 64: 1915-1919
71. Gupta RA, Dubois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 2001; 1: 11-21
72. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998; 93: 705-716
73. Lagorce C, Paraf F, Vidaud D, Couvelard A, Wendum D, Martin A, Fléjou JF. Cyclooxygenase-2 is expressed frequently and early in Barrett's oesophagus and associated adenocarcinoma. Histopathology 2003; 42: 457-465
74. Buttar NS, Wang KK, Leontovich O, Westcott JY, Pacifico RJ, Anderson MA, Krishnadath KK, Lutzke LS, Burgart LJ. Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology 2002; 122: 1101-1112
75. Corley DA, Kerlikowske K, Verma R, Buffler P. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 2003; 124: 47-56
76. Giovannucci E, Egan KM, Hunter DJ, Stampfer MJ, Colditz GA, Willett WC, Speizer FE. Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995; 333: 609-614
77. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 1994; 121: 241-246
78. Rahme E, Barkun AN, Toubouti Y, Bardou M. The cyclooxygenase-2-selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrence. Gastroenterology 2003; 125: 404-412
79. Kaur BS, Khamnehei N, Iravani M, Namburu SS, Lin O, Triadafilopoulos G. Rofecoxib inhibits cyclooxygenase 2 expression and activity and reduces cell proliferation in Barrett's esophagus. Gastroenterology 2002; 123: 60-67
80. Piazuelo E, Jimenez P, Lanas A. COX-2 inhibition in esophagitis, Barrett's esophagus and esophageal cancer. Curr Pharm Des 2003; 9: 2267-2280
81. Seva C, Dickinson CJ, Yamada T. Growth-promoting effects of glycine-extended progastrin. Science 1994; 265: 410-412
82. Hilsted L, Hint K, Christiansen J, Rehfeld JF. Neither glycineextended gastrin nor the 1-13 fragment of gastrin 17 influences gastric acid secretion in humans. Gastroenterology 1988; 94: 96-102
83. Matsumoto M, Park J, Sugano K, Yamada T. Biological activity of progastrin posttranslational processing intermediates. Am J Physiol 1987; 252: G315-G319
84. Jensen S, Borch K, Hilsted L, Rehfeld JF. Progastrin processing during antral G-cell hypersecretion in humans. Gastroenterology 1989; 96: 1063-1070
85. Ciccotosto GD, McLeish A, Hardy KJ, Shulkes A. Expression, processing, and secretion of gastrin in patients with colorectal carcinoma. Gastroenterology 1995; 109: 1142-1153
86. Rengifo-Cam W, Umar S, Sarkar S, Singh P. Antiapoptotic effects of progastrin on pancreatic cancer cells are mediated by sustained activation of nuclear factor-{kappa}B. Cancer Res 2007; 67: 7266-7274
87. Wu H, Owlia A, Singh P. Precursor peptide progastrin(1-80) reduces apoptosis of intestinal epithelial cells and upregulates cytochrome c oxidase Vb levels and synthesis of ATP. Am J Physiol Gastrointest Liver Physiol 2003; 285: G1097-G1110
88. Emoto K, Yamada Y, Sawada H, Fujimoto H, Ueno M, Takayama T, Kamada K, Naito A, Hirao S, Nakajima Y. Annexin II overexpression correlates with stromal tenascin-C overexpression: a prognostic marker in colorectal carcinoma. Cancer 2001; 92: 1419-1426
89. Vishwanatha JK, Chiang Y, Kumble KD, Hollingsworth MA, Pour PM. Enhanced expression of annexin II in human pancreatic carcinoma cells and primary pancreatic cancers. Carcinogenesis 1993; 14: 2575-2579
90. Ferrand A, Bertrand C, Portolan G, Cui G, Carlson J, Pradayrol L, Fourmy D, Dufresne M, Wang TC, Seva C. Signaling pathways associated with colonic mucosa hyperproliferation in mice overexpressing gastrin precursors. Cancer Res 2005; 65: 2770-2777
91. Azuma T, Magami Y, Habu Y, Kawai K, Taggart RT, Walsh JH. Carboxyl terminal glycine extended progastrin (gastrin-G) in gastric antral mucosa of patients with gastric or duodenal ulcer and in gastrinomas. J Gastroenterol Hepatol 1990; 5: 525-529
92. Beales IL, Ogunwobi O. Glycine-extended gastrin inhibits apoptosis in colon cancer cells via separate activation of Akt and JNK pathways. Mol Cell Endocrinol 2006; 247: 140-149
93. Hollande F, Imdahl A, Mantamadiotis T, Ciccotosto GD, Shulkes A, Baldwin GS. Glycine-extended gastrin acts as an autocrine growth factor in a nontransformed colon cell line. Gastroenterology 1997; 113: 1576-1588
94. Iwase K, Evers BM, Hellmich MR, Guo YS, Higashide S, Kim HJ, Townsend CM. Regulation of growth of human gastric cancer by gastrin and glycine-extended progastrin. Gastroenterology 1997; 113: 782-790
95. Koh TJ, Dockray GJ, Varro A, Cahill RJ, Dangler CA, Fox JG, Wang TC. Overexpression of glycine-extended gastrin in transgenic mice results in increased colonic proliferation. J Clin Invest 1999; 103: 1119-1126
96. Stepan VM, Krametter DF, Matsushima M, Todisco A, Delvalle J, Dickinson CJ. Glycine-extended gastrin regulates HEK cell growth. Am J Physiol 1999; 277: R572-R581
97. Patel O, Marshall KM, Bramante G, Baldwin GS, Shulkes A. The C-terminal flanking peptide (CTFP) of progastrin inhibits apoptosis via a PI3-kinase-dependent pathway. Regul Pept 2010; 165: 224-231
98. Ottewell PD, Varro A, Dockray GJ, Kirton CM, Watson AJ, Wang TC, Dimaline R, Pritchard DM. COOH-terminal 26-amino acid residues of progastrin are sufficient for stimulation of mitosis in murine colonic epithelium in vivo. Am J Physiol Gastrointest Liver Physiol 2005; 288: G541-G549